文献速递心外重症与机械循环支持

心脏移植术中血管麻痹综合征的系统评价与荟萃分析

Vasoplegic syndrome during heart transplantation: A systematic review and meta-analysis.
PubMed 文献 · J Heart Lung Transplant · 2024-02-28

该系统评价纳入22篇文献,心脏移植术中血管麻痹综合征(VS)患病率为28.72%(95%CI 27.37%, 30.10%)。男性、较高体重指数、甲状腺功能减退、移植前使用左心室辅助装置或VA-ECMO、移植前使用钙通道阻滞剂或胺碘酮、较长体外循环时间及较高输血需求与VS相关。发生VS者术后更可能需要VA-ECMO支持、肾脏替代治疗、因出血再手术、延长机械通气,且30天和1年死亡率更高。

要点

  • 心脏移植术中血管麻痹综合征患病率为28.72%(95%CI 27.37%, 30.10%)。
  • 相关因素包括男性、较高体重指数、甲状腺功能减退、移植前左心室辅助装置或VA-ECMO、钙通道阻滞剂或胺碘酮使用、较长体外循环时间及较高输血需求。
  • 发生VS者术后VA-ECMO支持、肾脏替代治疗、因出血再手术、延长机械通气及30天和1年死亡率更高。

核心结论

  • 该系统评价结果为临床医生识别高危患者和潜在风险缓解途径提供了初步数据。
  • 建立正式定义VS的指南将有助于心脏移植期间精确诊断并指导治疗。
  • 未来需要针对难治性VS治疗策略的研究。

研究设计与样本

  • 系统评价与荟萃分析,检索所有已发表的关于心脏移植术中血管麻痹综合征的文献,最终纳入22篇出版物。
  • 收集数据包括心脏移植人群中VS的发生率、患者及术中特征以及术后结局。

主要发现

  • 心脏移植术中血管麻痹综合征的患病率为28.72%(95%CI 27.37%, 30.10%)。
  • 与VS相关的因素包括男性、较高体重指数、甲状腺功能减退、移植前左心室辅助装置或VA-ECMO、移植前钙通道阻滞剂或胺碘酮使用、较长体外循环时间及较高输血需求。
  • 发生VS的患者更可能需要术后VA-ECMO支持、肾脏替代治疗、因出血再手术、延长机械通气以及更高的30天和1年死亡率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vasoplegic syndrome (VS) is a common occurrence during heart transplantation (HT). It currently lacks a uniform definition between transplant centers, and its pathophysiology and treatment remain enigmatic. This systematic review summarizes the available published clinical data regarding VS during HT. METHODS: We searched databases for all published reports on VS during HT. Data collected included the incidence of VS in the HT population, patient and intraoperative characteristics, and postoperative outcomes. RESULTS: Twenty-two publications were included in this review. The prevalence of VS during HT was 28.72% (95% confidence interval: 27.37%, 30.10%). Factors associated with VS included male sex, higher body mass index, hypothyroidism, pre-HT left ventricular assist device or venoarterial extracorporeal membrane oxygenation (VA-ECMO), pre-HT calcium channel blocker or amiodarone usage, longer cardiopulmonary bypass time, and higher blood product transfusion requirement. Patients who developed VS were more likely to require postoperative VA-ECMO support, renal replacement therapy, reoperation for bleeding, longer mechanical ventilation, and a greater 30-day and 1-year mortality. CONCLUSIONS: The results of our systematic review are an initial step for providing clinicians with data that can help identify high-risk patients and avenues for potential risk mitigation. Establishing guidelines that officially define VS will aid in the precise diagnosis of these patients during HT and guide treatment. Future studies of treatment strategies for refractory VS are needed in this high-risk patient population.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Kumar N, Fitzsimons MG, Iyer MH, et al. Vasoplegic syndrome during heart transplantation: A systematic review and meta-analysis. J Heart Lung Transplant. 2024. PMID: 38428755. doi:10.1016/j.healun.2024.02.1458

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。